108 related articles for article (PubMed ID: 1100914)
21. Rescue of thymidine cytotoxicity in L1210 ascites by elevated endogenous levels of deoxycytidine.
Egan EM; Sargent L; Rosowsky A; Kufe DW
Cancer Treat Rep; 1981; 65(9-10):853-60. PubMed ID: 7273018
[TBL] [Abstract][Full Text] [Related]
22. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
23. [The parameters of bone marrow cell proliferation under the action of genotoxic agents].
Shmarov DA; Pershin VN
Vestn Ross Akad Med Nauk; 1993; (4):8-12. PubMed ID: 7687490
[No Abstract] [Full Text] [Related]
24. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
25. Long-term bone marrow culture as a model for host toxicity: the effect of methotrexate on hematopoiesis and adherent layer function.
Williams LH; Udupa KB; Lipschitz DA
Exp Hematol; 1988 Jan; 16(1):80-7. PubMed ID: 3257191
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
[TBL] [Abstract][Full Text] [Related]
27. [Cellular mechanism of the antileukemic action of quinoline dibromide].
Golenko OD; Paramonova TD; Nikolaeva TG
Biull Eksp Biol Med; 1984 Jul; 98(7):59-61. PubMed ID: 6466833
[TBL] [Abstract][Full Text] [Related]
28. Histidinol-mediated improvement in the specificity of 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil in L 1210 leukemia-bearing mice.
Warrington RC; Muzyka TG; Fang WD
Cancer Res; 1984 Jul; 44(7):2929-35. PubMed ID: 6722819
[TBL] [Abstract][Full Text] [Related]
29. Screening of cytotoxic drugs for residual bone marrow damage.
Trainor KJ; Morley AA
J Natl Cancer Inst; 1976 Dec; 57(6):1237-9. PubMed ID: 1003558
[TBL] [Abstract][Full Text] [Related]
30. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P; Cerna I
Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
[TBL] [Abstract][Full Text] [Related]
31. Studies of the antitumor action of 5-fluorouracil (FU).
Mandel HG; Klubes P; Fernandes DJ
Bull Cancer; 1979; 66(1):49-54. PubMed ID: 420946
[No Abstract] [Full Text] [Related]
32. Chemotherapy and the life cycle of leukaemic cells. A comparison between the growth characteristics of human acute leukaemia and the murine leukaemia L 1210.
Benckhuijsen C
Folia Med Neerl; 1969 Dec; 12(2):74-84. PubMed ID: 4894168
[No Abstract] [Full Text] [Related]
33. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642
[TBL] [Abstract][Full Text] [Related]
34. Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man.
Liss RH; Chadwick M
Cancer Chemother Rep; 1974; 58(6):777-86. PubMed ID: 4475611
[No Abstract] [Full Text] [Related]
35. The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects.
Tattersall MH; Brown B; Frei E
Nature; 1975 Jan; 253(5488):198-200. PubMed ID: 1078601
[No Abstract] [Full Text] [Related]
36. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
37. Cain's quinolinium (NSC 176319): protection of murine L1210 leukemia cells and bone marrow progenitor cells against mechlorethamine cytotoxicity and its application to combination chemotherapy.
Naujokaitis SA
Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):97-104. PubMed ID: 7313308
[TBL] [Abstract][Full Text] [Related]
38. Determination of therapeutic index of drugs by in vitro sensitivity tests using human host and tumor cell suspensions.
Tisman G; Herbert V; Edlis H
Cancer Chemother Rep; 1973 Feb; 57(1):11-9. PubMed ID: 4704096
[No Abstract] [Full Text] [Related]
39. Methotrexate-thymidine treatment of murine leukemia.
Tattersall MH; Brown BL; Frei E
Ann N Y Acad Sci; 1975 Aug; 255():261-5. PubMed ID: 1081356
[No Abstract] [Full Text] [Related]
40. EXPERIMENTAL CHEMOTHERAPY STUDIES. V. THE COLLATERAL SENSITIVITY TO ALKYLATING AGENTS OF SEVERAL ANTIMETABOLITE-RESISTANT ASCITES TUMORS IN MICE.
RUTMAN RJ
Cancer Res; 1964 May; 24():634-8. PubMed ID: 14188466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
